Invisible Illness Awareness Week 2016: Our Voices Need to Be Heard
Never heard of Invisible Illness Awareness Week? You're not alone. Jody Smith sheds a little light to make it more visible
Discuss the article on the Forums.

Cytokine inhibition - a randomized placebo-controlled, double-blind trial

Discussion in 'Latest ME/CFS Research' started by Marky90, Oct 7, 2015.

  1. Marky90

    Marky90 Science breeds knowledge, opinion breeds ignorance

    Messages:
    1,227
    Likes:
    4,571
    leokitten, Woolie, nandixon and 2 others like this.
  2. snowathlete

    snowathlete

    Messages:
    3,312
    Likes:
    14,618
    UK
    I think the idea of trialing various cytokine inhibitory drugs is potentially a good idea. They are talking about starting with a trial of anakinra which is used in RA to inhibit IL-1. @Jonathan Edwards - is this a worthwhile endeavour in your opinion?
     
  3. John Mac

    John Mac Senior Member

    Messages:
    318
    Likes:
    1,521
    Liverpool UK
    " The results of this study may expand treatment options for patients with CFS, for whom graded exercise therapy and cognitive behavioral therapy are the only evidence-based interventions that exist at this moment."

    Really? What about Rituximab?
     
  4. Marky90

    Marky90 Science breeds knowledge, opinion breeds ignorance

    Messages:
    1,227
    Likes:
    4,571
    Yeah... I hope they just haven`t heard of it. This kinda proves what i already fear: that most people don`t actually read the studies that are supposed to prove that CBT and graded exercise therapy works.. They seem to often take the conclusion for fact.
     
    Woolie likes this.
  5. lansbergen

    lansbergen Senior Member

    Messages:
    2,509
    Likes:
    2,718
    This lot is in bed with the weasel.
     
    mango, jimells and Effi like this.
  6. snowathlete

    snowathlete

    Messages:
    3,312
    Likes:
    14,618
    UK
    Although it's annoying, I think their point is that GET and CBT are the only approved treatments at the moment (even though the eveidence for them is actually shockingly bad - wish they had therefore not referred to them as "evidence-based") and although Rituximab already has better evidence than all the GET and CBT studies put together it is not a recognised, approved treatment yet, and it wont be until at least the Norwegian phase 3 study is out.
     
  7. Simon

    Simon

    Messages:
    1,927
    Likes:
    14,578
    Monmouth, UK
    Note this is a protocol for a planned study.

    I actually think the idea is pretty good idea, not least because of what it might reveal about mechanisms (as opposed to treatment options). If the IL-1 inhibitor anakinra reduces fatigue, it's evidence that IL-1 plays a role in fatigue. And anakinra apparently crosses the blood brain barrier, so if IL-1 plays a pathological role in the brain, anakinra could help identify that too.



    Cytokine inhibition in chronic fatigue syndrome patients: study protocol for a randomized controlled trial.
    Roerink ME1, Knoop H2, Bredie SJ3, Heijnen M4, Joosten LA5, Netea MG6, Dinarello CA7, van der Meer JW8.
    Author information
    Abstract

    BACKGROUND:
    Chronic fatigue syndrome (CFS) is a medically unexplained syndrome for which no somatic or pharmacological treatment has been proven effective. Dysfunction of the cytokine network has been suspected to play a role in the pathophysiology of CFS. The disturbances of the cytokine network detected in CFS patients are highly variable, in part due to the lack of adequate controls in many studies. Furthermore, all studies have been performed on peripheral venous blood of patients. As cytokines mainly act in tissues, for example, the brain, the information that can be derived from peripheral blood cells is limited. The information regarding the possible role of cytokines in the pathophysiology could come from intervention studies in which the activities of relevant cytokines are reduced, for example, reducing interleukin-1, interleukin-6 or tumor necrosis factor. In this study, the clinical usefulness of anakinra, an IL-1 antagonist, will be assessed in patients with CFS.

    METHODS/DESIGN:
    A randomized placebo-controlled, double-blind trial will be conducted. Fifty adult female patients meeting the Centers for Disease Control (CDC) criteria for CFS and without psychiatric co-morbidity will be included. After inclusion, patients will be randomized between treatment with anakinra (recombinant human interleukin-1 receptor antagonist) or placebo. Each group will be treated for 4 weeks. Outcome measures will be assessed at baseline, after 4 weeks of intervention, and 6 months after baseline assessment. The primary outcome measure will be fatigue severity at 4 weeks, measured with the validated Checklist of Individual Strength (CIS). Secondary outcome measures are functional impairment, physical and social functioning, psychological distress, pain severity, presence of accompanying symptoms, and cytokine and cortisol concentrations.

    DISCUSSION:
    This is the first randomized placebo-controlled trial that will evaluate the effect of interference with IL-1 on the experience of fatigue in patients with CFS. The results of this study may expand treatment options for patients with CFS, for whom graded exercise therapy and cognitive behavioral therapy are the only evidence-based interventions that exist at this moment.

    TRIAL REGISTRATION:
    Clinicaltrials.gov: NCT02108210 . Clinicaltrials.gov registration date: 8 April 2014. EudraCT: 2013-005466-19.
     
  8. snowathlete

    snowathlete

    Messages:
    3,312
    Likes:
    14,618
    UK
    Knoop's name is on a few dodgy papers, as is Van der Meer's. The others don't seem to have much history, and I don't know anything about them.
     
    Bob and Marky90 like this.
  9. snowathlete

    snowathlete

    Messages:
    3,312
    Likes:
    14,618
    UK
    Valentijn and Woolie like this.
  10. Sidereal

    Sidereal Senior Member

    Messages:
    3,097
    Likes:
    17,189
  11. Valentijn

    Valentijn Senior Member

    Messages:
    14,281
    Likes:
    45,850
    Useless bullshit. It's a cytokine treatment trial, but cytokines are only a secondary measure, and all of the focus is on fatigue. Get rid of the psychobabbler and use your brains.
     
    leokitten, Woolie, SOC and 3 others like this.
  12. Gijs

    Gijs Senior Member

    Messages:
    649
    Likes:
    1,324
    Why don't they measure these cytokines before and after treatment? This is how real objective science works. Otherwise it is sloppy science. Still i do hope it works but i doubt it.
     
    Woolie and jimells like this.
  13. Bob

    Bob

    Messages:
    9,868
    Likes:
    34,214
    England (south coast)
    Fukuda!

    Also, will they only select patients who test for abnormal levels of IL-1 or will there be no attempt at a rigorous trial methodology? Are they just going to randomly include all Fukuda CFS patients (without psychiatric comorbidity) whatever their cytokine levels? If so then... Doh! Fail! #yetanotherwasteofresources
     
    Woolie, SOC, jimells and 3 others like this.
  14. Jonathan Edwards

    Jonathan Edwards "Gibberish"

    Messages:
    5,250
    Likes:
    32,015
    I think this has to be worth trying, although the absence of raised CRP in ME suggests that symptoms are probably not generated by a typical IL-1 and TNF cytokine drive. TNF inhibitors have already been tried and I think the trials were discontinued for unpromising results.
     
  15. Jonathan Edwards

    Jonathan Edwards "Gibberish"

    Messages:
    5,250
    Likes:
    32,015
    The authors will be well aware of the quality of data for CBT and GET, of the recent debate about that and the rituximab data. I think it is fair to say that we do not yet have a formal evidence base for rituximab, but that probably applies to CBT and GET as well.
     
    leokitten, Woolie and Marky90 like this.
  16. Jonathan Edwards

    Jonathan Edwards "Gibberish"

    Messages:
    5,250
    Likes:
    32,015
    Charles Dinarello more or less discovered IL-1 - i.e. he sort of invented cytokines. If he is taking an interest in IL-1 in ME that should be worth a glass of Cava, if not Champagne.
     
    leokitten, nandixon, Simon and 9 others like this.
  17. Jonathan Edwards

    Jonathan Edwards "Gibberish"

    Messages:
    5,250
    Likes:
    32,015
    I am not sure I agree about that. IL-1 might well be acting locally, with nothing to find in the blood. Doing blood levels would be sensible and I expect they will do them, but they certainly should not be the primary outcome measure. If you think about it showing that an IL-1 inhibitor inhibits IL-1 in PWME tells you nothing whatsoever about ME - just that you put the right drug in the bottle. The end point is designed to show that in PWME the inhibitor benefits symptoms - i.e. fatigue, so fatigue is precisely the right endpoint!
     
    cigana, leokitten, adreno and 4 others like this.
  18. Bob

    Bob

    Messages:
    9,868
    Likes:
    34,214
    England (south coast)
    This is from the full protocol. It's a secondary outcome to be measured at baseline, and directly following the intervention, and at 6 months...
     
    Last edited: Oct 7, 2015
    Woolie and Marky90 like this.
  19. Effi

    Effi Senior Member

    Messages:
    1,491
    Likes:
    4,554
    Europe
    They're all from Radboud Nijmegen (the Netherlands). They're the ones who throw CBT at everything (MS, post-cancer fatigue, post-polio syndrome, cfs, ...). One patient who was in this trial said that they offered voluntary CBT to everyone in the trial, almost like an incentive I guess in their minds? :rolleyes:
     
  20. Valentijn

    Valentijn Senior Member

    Messages:
    14,281
    Likes:
    45,850
    My CRP was raised the one time it was tested :D
     
    SOC likes this.

See more popular forum discussions.

Share This Page